Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent rel...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Mukherjee, Nabanita, Almeida, Adam, Partyka, Katie A., Lu, Yan, Schwan, Josianna V., Lambert, Karoline, Rogers, Madison, Robinson, William A, Robinson, Steven E, Applegate, Allison J, Amato, Carol M, Luo, Yuchun, Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356684/
https://ncbi.nlm.nih.gov/pubmed/27829238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13141
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia